TrialRespiratory research2011

Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial.

Anthony D'Urzo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.